Application of the adenosine triphosphate‐cell viability assay in human breast cancer chemosensitivity testing: A report on the first results

Koechli, Ossi R.; Sevin, Bernd‐Uwe; Avner, Barry P.; Perras, James P.; Robinson, David S.; Averette, Hervy E.

doi:10.1002/jso.2930540213

Cited by 28 publications

(16 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This assay shows good correlation with both clonogenic and non-clonogenic assays [21,24] and has been proved to be applicable for chemosensitivity testing of tumor lines [25,26] and clinical tumors, as well [19,20,27,28]. Promising in vitro~in vivo correlations with ATPbased chemosensitivity assays have already been reported by us and by others [22,[29][30][31]. The ATP-TCA was thus regarded as a suitable model to evaluate the cytotoxicity of DOX versus MX in native BC cells.…”

Section: Introductionmentioning

confidence: 62%

Heterogeneity ofin vitro chemosensitivity in perioperative breast cancer cells to mitoxantroneversus doxorubicin evaluated by a microplate ATP bioluminescence assay

Kurbacher

Cree

Brenne

et al. 1996

Breast Cancer Res Tr

View full text Add to dashboard Cite

Apart from clinical trials, mitoxantrone (MX) is rarely used in breast cancer (BC) due to the anticipated anthracycline cross-resistance. We have examined this drug versus doxorubicin (DOX) using data obtained from in vitro microplate ATP tumor chemosensitivity assays (ATP-TCA) of BC cells which were derived from 55 chemotherapy-naive patients at time of primary surgery. Both drugs were tested at 6 different concentrations ranging from 6.25% to 200% peak plasma concentration in vivo (PPC). Differences between DOX and MX observed for mean IC50, IC90, and a sensitivity index (SI) were not statistically significant. In vitro response rates were 44% for DOX and 52% for MX. 34 of 52 eligible assays (65%) showed comparable activity of both drugs whereas a lack of cross-resistance was observed in the remaining 18 (35%) tumors as indicated by differences for SI. Cumulative concentration-response plots of tumors responding in vitro with a > or = 50 percent or > or = 90 percent tumor cell inhibition showed a strong dose-dependence for both DOX and MX at concentrations which normally can be achieved within clinical tumors (i.e. 6.25%-50% PPC). At higher concentrations, however, cytotoxicity of DOX and MX could not be improved by further in vitro dose escalation. Moreover, a substantial proportion of BC specimens (DOX: 48.1%; MX: 40.4%) did not experience a > or = 90 tumor cell inhibition at 200% PPC. In conclusion, in vitro results obtained by ATP-TCA indicate that there is no cross-resistance between MX and DOX in a substantial proportion of BC patients. This may be clinically useful and suggests that combinations including MX should be tested in patients clinically resistant to DOX containing regimens. Since both drugs produced sigmoidal concentration-response curves, dose escalation beyond a certain point may not produce increased sensitivity.

show abstract

Section: Introductionmentioning

confidence: 62%

Heterogeneity ofin vitro chemosensitivity in perioperative breast cancer cells to mitoxantroneversus doxorubicin evaluated by a microplate ATP bioluminescence assay

Kurbacher

Cree

Brenne

et al. 1996

Breast Cancer Res Tr

View full text Add to dashboard Cite

show abstract

“…The majority of our data with fresh tumors were collected using the agar/ McCoy underlayer [3], However, it is evident that the growth of fibroblasts can also be inhibited with the aga rose-coated 96-well plates. Present data indicate that with this latter culture technique sufficient growth of tumor cells can be obtained [25][26][27], Therefore, this alternative method could be used to plate cells for the ATP-CVA, e.g., in enriched RPMI. The agarose-coated wells can be pre pared faster and are more cost effective.…”

Section: Discussionmentioning

confidence: 99%

Growth Characteristics of Nonmalignant Cells in the ATP Cell Viability Assay

et al. 1994

Self Cite

View full text Add to dashboard Cite

Over the last 5 years, the ATP cell viability assay (ATP-CVA) has been used to study the in vitro response of cell lines and fresh gynecologic human tumors to a variety of antineoplastic agents including chemotherapeutic agents, hormones and biological response modifiers. This assay measures light production as intracellular ATP interacts with the luciferin-luciferase complex. Quantitation of the light produced has been shown to directly correspond with the number of viable cells. A past criticism is that in the ATP-CVA, when applied to fresh tumor tissue, normal cells (fibroblasts, macrophages and lymphocytes) also produce ATP, and if present in sufficient numbers, could lead to errors in chemosensitivity testing results. This study was designed to evaluate the growth characteristics of various benign cells found in fresh tumors. The cells were studied under multiple plating conditions to show the relative increase or decrease of fractional ATP measured at different time points. We found that agar/McCoy underlayer and agarose-coated wells do not permit the growth of nonmalignant cells. In the culture conditions of the ATP-CVA, nonmalignant cells do not contribute relevant ATP levels when treated samples are compared to controls on day 6. Therefore, results of the ATP-CVA in fresh tumors should not be affected.

show abstract

“…9 The adenosine triphosphate (ATP)-based assay is a sensitive assay that evaluates tumor cell viability by measuring the intracellular ATP levels of drugexposed cells and untreated controls. 6,[10][11][12][13] This assay has been somewhat widely studied because its reliability was demonstrated as a sensitive measure of viability in the field of cell biology. 14,15 In this study we modified previous ATP-based assays.…”

mentioning

confidence: 99%

Adenosine triphosphate‐based chemotherapy response assay (ATP‐CRA)‐guided platinum‐based 2‐drug chemotherapy for unresectable nonsmall‐cell lung cancer

Moon

Choi

Kim³

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND.The study investigated correlations between adenosine triphosphate / chemotherapy response assay (ATP‐CRA) and clinical outcomes after ATP‐CRA‐guided platinum‐based chemotherapy for unresectable nonsmall‐cell lung cancer (NSCLC).METHODS.The authors performed an in vitro chemosensitivity test, ATP‐CRA, to evaluate the chemosensitivities of anticancer drugs such as cisplatin, carboplatin, paclitaxel, docetaxel, gemcitabine, and vinorelbine for chemonaive, unresectable NSCLC. The cell death rate was determined by measuring the intracellular ATP levels of drug‐exposed cells compared with untreated controls. A sensitive drug was defined as a drug producing 30% or more reduction in ATP compared with untreated controls. Assay‐guided platinum‐based 2‐drug chemotherapy was given to patients with pathologically confirmed NSCLC.RESULTS.Thirty‐four patients were enrolled. Thirty tumor specimens were obtained by bronchoscopic biopsies and 4 obtained surgically. The median age was 61 years and 27 patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1. The response rate was 43.8%. At a median follow‐up period of 16.9 months, the median progression‐free and overall survivals were 3.6 and 11.2 months, respectively. Patients were dichotomized into the platinum‐sensitive (S; 20 patients) and resistant (R; 14 patients) groups. The positive/negative predictive values were 61.1% and 78.6% with a predictive accuracy of 68.8%. Although without significant differences in pretreatment parameters, the S‐group showed better clinical response (P = .036), longer progression‐free survival (P = .060), and longer overall survival (P = .025).CONCLUSIONS.Despite using bronchoscopic biopsied specimens, ATP‐CRA and clinical outcomes correlated well after assay‐guided platinum‐based 2‐drug chemotherapy for unresectable NSCLC. There was a favorable response and survival in the platinum‐sensitive vs resistant groups. Cancer 2007. © 2007 American Cancer Society.

show abstract

Application of the adenosine triphosphate‐cell viability assay in human breast cancer chemosensitivity testing: A report on the first results

Cited by 28 publications

References 28 publications

Heterogeneity ofin vitro chemosensitivity in perioperative breast cancer cells to mitoxantroneversus doxorubicin evaluated by a microplate ATP bioluminescence assay

Heterogeneity ofin vitro chemosensitivity in perioperative breast cancer cells to mitoxantroneversus doxorubicin evaluated by a microplate ATP bioluminescence assay

Growth Characteristics of Nonmalignant Cells in the ATP Cell Viability Assay

Adenosine triphosphate‐based chemotherapy response assay (ATP‐CRA)‐guided platinum‐based 2‐drug chemotherapy for unresectable nonsmall‐cell lung cancer

Contact Info

Product

Resources

About